Leerink Partners Reiterates Market Perform Rating on Halozyme Therapeutics (HALO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Leerink Partners Reiterates Market Perform Rating on Halozyme Therapeutics (HALO)
October 3, 2024 2:18 PM EDT
TD Cowen analyst Brendan Smith reiterated a Buy rating and $65.00 price target on Halozyme Therapeutics (NASDAQ: HALO).
The analyst commented, "ARGX/HALO expanded their existing ENHANZE collaboration w/ 4 new targets for $7.5M upfront each ($30M total) + tiered mid-single-digit royalties. News adds to Vyvgart Hytrulo... More
October 3, 2024 8:01 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE® for a total of six targets, including for the neonatal Fc receptor (FcRn) target. VYVGART® Hytrulo, argenx's branded FcRn blocker, is approved by the... More
